Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASBP Aspire Biopharma	$0.59 +64.3%	$0.36	$0.22 ▼ $15.80	$17.78M	0.79	826,444 shs	466.15 million shs
CMMB Chemomab Therapeutics	$0.94 +1.1%	$1.11	$0.87 ▼ $2.55	$17.54M	0.52	126,395 shs	90,117 shs
PULM Pulmatrix	$4.71	$6.35	$1.78 ▼ $10.40	N/A	1.45	10,359 shs	11,029 shs
VIVS VivoSim Labs	$1.81 +2.3%	$1.77	$1.41 ▼ $21.96	$4.60M	0.94	53,655 shs	17,773 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASBP Aspire Biopharma	0.00%	+6.85%	+0.28%	+35,899,900.00%	+35,899,900.00%
CMMB Chemomab Therapeutics	0.00%	-4.11%	-17.70%	-33.09%	-16.22%
PULM Pulmatrix	0.00%	-7.10%	-25.65%	-27.54%	+132.02%
VIVS VivoSim Labs	0.00%	+1.43%	-6.35%	+176,999,900.00%	+176,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASBP Aspire Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CMMB Chemomab Therapeutics	3.4564 of 5 stars	3.5	5.0	0.0	0.0	3.1	1.7	0.6
PULM Pulmatrix	1.1881 of 5 stars	0.0	5.0	0.0	0.0	4.1	0.0	0.0
VIVS VivoSim Labs	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASBP Aspire Biopharma	0.00	N/A	N/A	N/A
CMMB Chemomab Therapeutics	3.00	Buy	$8.50	804.26% Upside
PULM Pulmatrix	0.00	N/A	N/A	N/A
VIVS VivoSim Labs	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASBP Aspire Biopharma	N/A	N/A	N/A	N/A	($2.17) per share	N/A
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$0.72 per share	N/A
PULM Pulmatrix	$7.81M	N/A	N/A	N/A	$2.45 per share	N/A
VIVS VivoSim Labs	$142K	33.14	N/A	N/A	$5.54 per share	0.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASBP Aspire Biopharma	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	-737.96%	N/A
CMMB Chemomab Therapeutics	-$13.94M	-$0.59	N/A	N/A	N/A	N/A	-88.15%	-70.00%	8/20/2025 (Estimated)
PULM Pulmatrix	-$6.94M	-$2.17	N/A	∞	N/A	-122.46%	-97.25%	-88.96%	11/6/2025 (Estimated)
VIVS VivoSim Labs	-$2.48M	-$10.20	N/A	∞	N/A	-1,396.48%	-32.95%	-21.31%	N/A

Latest VIVS, PULM, ASBP, and CMMB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CMMB Chemomab Therapeutics	-$0.20	-$0.09	+$0.11	-$0.09	N/A	N/A
8/13/2025	Q2 2025	ASBP Aspire Biopharma	N/A	-$0.04	N/A	-$0.04	N/A	N/A
8/12/2025	Q1 2026	VIVS VivoSim Labs	N/A	-$1.14	N/A	-$1.14	N/A	$0.04 million
8/6/2025	Q2 2025	PULM Pulmatrix	N/A	-$0.42	N/A	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASBP Aspire Biopharma	N/A	N/A	N/A	N/A	N/A
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
PULM Pulmatrix	N/A	N/A	N/A	N/A	N/A
VIVS VivoSim Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASBP Aspire Biopharma	N/A	0.09	0.09
CMMB Chemomab Therapeutics	N/A	5.33	5.33
PULM Pulmatrix	N/A	11.21	11.21
VIVS VivoSim Labs	N/A	4.52	4.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASBP Aspire Biopharma	19.17%
CMMB Chemomab Therapeutics	46.05%
PULM Pulmatrix	11.84%
VIVS VivoSim Labs	8.23%

Insider Ownership

Company	Insider Ownership
ASBP Aspire Biopharma	48.00%
CMMB Chemomab Therapeutics	11.91%
PULM Pulmatrix	0.62%
VIVS VivoSim Labs	3.72%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASBP Aspire Biopharma	N/A	49.53 million	25.75 million	N/A
CMMB Chemomab Therapeutics	20	18.86 million	16.61 million	Not Optionable
PULM Pulmatrix	20	N/A	N/A	Not Optionable
VIVS VivoSim Labs	20	2.60 million	2.50 million	N/A

VIVS, PULM, ASBP, and CMMB Headlines

Recent News About These Companies

VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

August 14, 2025 | finanznachrichten.de

VivoSim appoints Lialin as Chief Commercial Officer

August 14, 2025 | msn.com

VivoSim Labs, Inc. Appoints Tony Lialin as Chief Commercial Officer to Drive Growth in 3D Drug Testing Services

August 14, 2025 | quiverquant.comQ

VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

August 14, 2025 | financialpost.comF

VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

August 14, 2025 | globenewswire.com

VivoSim: Fiscal Q1 Earnings Snapshot

August 12, 2025 | timesunion.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIVS, PULM, ASBP, and CMMB Company Descriptions

Aspire Biopharma NASDAQ:ASBP

$0.59 +0.23 (+64.35%)

As of 04:00 PM Eastern

Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.

Chemomab Therapeutics NASDAQ:CMMB

$0.94 +0.01 (+1.08%)

Closing price 04:00 PM Eastern

Extended Trading

$0.98 +0.04 (+4.36%)

As of 07:51 PM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Pulmatrix NASDAQ:PULM

$4.76 +0.05 (+0.98%)

As of 04:00 PM Eastern

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

VivoSim Labs NASDAQ:VIVS

$1.81 +0.04 (+2.26%)

As of 03:59 PM Eastern

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time